In conclusion, although PPARγ agonists offer benefits in the treatment of diabetes and atherosclerosis, known risk factors associated with cardiovascular disease, they also have deleterious effects such as increased risk incidence of myocardial infarction and heart failure. This evidence concerns the gene PPARG and myocardial infarction.